Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 20, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details within employee benefit trusts and retirement plans.
Material Changes
Material changes reported relate to specific share movements within employee funds:
- SmithKline Beecham Employee Benefit Trust: On June 16, 2005, 171 Ordinary shares were sold at £13.46 per share, and 504 Ordinary shares were transferred to a participant in the Annual Investment Plan.
- GlaxoSmithKline US Retirement Savings Plan: On June 16, 2005, the number of Ordinary Share ADRs held by the fund decreased from 18,305,200 to 18,293,564 at an average price of $50.25.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a routine disclosure regarding director interests in discretionary funds.
Important Facts for Investors
- Directors J S Heslop, Dr J P Garnier, and Dr T Yamada have potential interests in shares held within the respective employee benefit trusts.
- The reported share transactions were executed on behalf of participants in the Annual Investment Plan and US Retirement Savings Plan, not as direct personal trades by the directors.
- No financial performance data is included in this specific filing.